RIPK1-IN-9

CAS No. 2682889-57-0

RIPK1-IN-9( —— )

Catalog No. M35690 CAS No. 2682889-57-0

RIPK1-IN-9 is a potent and selective inhibitor of RIPK1, a dihydronaphthone compound, which inhibits U937 and L929 cells with an IC50 of 2 nM and 1.3 nM, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 547 Get Quote
5MG 823 Get Quote
10MG 1131 Get Quote
25MG 1628 Get Quote
50MG 2190 Get Quote
100MG 2898 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    RIPK1-IN-9
  • Note
    Research use only, not for human use.
  • Brief Description
    RIPK1-IN-9 is a potent and selective inhibitor of RIPK1, a dihydronaphthone compound, which inhibits U937 and L929 cells with an IC50 of 2 nM and 1.3 nM, respectively.
  • Description
    RIPK1-IN-9 (example 45), a dihydronaphthyridone compound, is a potent and selective RIPK1 inhibitor. RIPK1-IN-9 inhibits U937 cell (IC50=2 nM) and L929 cell (IC50=1.3 nM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    RIP kinase
  • Recptor
    RIP kinase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2682889-57-0
  • Formula Weight
    472.51
  • Molecular Formula
    C26H25FN6O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C1C=2C(=NC=C(C2)C3=CC=4N(C=C3)N=C(N)N4)CCN1CC5=C(OC6CCCC6)C=CC(F)=C5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Fusheng Zhou, et al. Dihydronaphthyridone compounds, their preparation and pharmaceutical uses. WO2021160109A1.
molnova catalog
related products
  • RIPK1-IN-7

    RIPK1-IN-7 is a potent and selective inhibitor of RIPK1(Kd of 4 nM and an enzymatic IC50 of 11 nM),andexhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model.

  • Cpd27

    Cpd27 (TIE-2/VEGFR-2 kinase-IN-2) is a TIE-2 and VEGFR-2 inhibitor that inhibits RIPK1 and protects RGCs from TNF-stimulated cell death and can be used to study glaucoma.

  • GSK2593074A

    GSK2593074A (GSK'074, GSK-2593074A) is novel potent, selective RIP1/RIP3 kinase dual inhibitor.